Can International Patients Join Interventional Myeloma Clinical Trials in China?

Core Conclusion

If you are an international patient or caregiver seeking advanced multiple myeloma therapies in China, you must know the regulatory baseline:

Under current Chinese regulatory and human genetic resource laws, overseas international patients are almost universally ineligible to enroll in interventional clinical trials in mainland China.

Commercial agencies advertising "free or low-cost experimental CAR-T trials in China for foreign patients" are misrepresenting the healthcare reality. Below is an objective overview of the regulatory boundaries and legitimate pathways.

1. Regulatory Barriers: Human Genetic Resources and IRB Standards

Mainland China regulates clinical drug development under the National Medical Products Administration (NMPA) and the Ministry of Science and Technology:

1. Human Genetic Resources Administration of China (HGRAC) Regulations: Under the Regulations on the Management of Human Genetic Resources, all biological sampling, genomics, and cellular handling are subject to stringent oversight. Including foreign citizens in domestic registrational studies requires complex international approvals that commercial sponsors rarely seek for domestic clinical trial sites.
2. Residency and Medical Accountability: Interventional trials in hematology require emergency multi-system support, predictable rescue pathways, and multi-year survivorship tracking. Hospitals are legally and ethically accountable for long-term safety, making non-resident medical tourists without local social support unviable for experimental cohorts.
3. Mandatory National Identification: Hospital electronic medical record systems and trial electronic data capture (EDC) databases are integrated with Chinese national resident identification numbers.

2. Recognizing Misleading Intermediary Claims

With the global prominence of Chinese BCMA CAR-T and bispecific clinical data, unethical medical brokers have targeted overseas families. Be vigilant against common red flags:

• 🚩 "Guaranteed clinical trial spot for a $20,000 finder's fee": In China, clinical trial enrollment is completely free and strictly decided by the Principal Investigator (PI) based on clinical protocol match—never sold by third parties.
• 🚩 "Special investigator-initiated trial (IIT) for foreigners": Hospital Ethics Committees (IRBs) in China do not approve investigator trials designed to bypass commercial pricing for foreign medical tourists.
• 🚩 Refusal to name the exact hospital or licensed product: Legitimate academic medical centers (such as Peking University People's Hospital, Ruijin Hospital, or West China Hospital) never solicit foreign patients through anonymous social media brokers.

3. The Lawful Alternative: Commercial CAR-T at Licensed Centers

While experimental clinical trials are closed to non-residents, international patients can lawfully access China's approved commercial cellular therapies:

• NMPA-Approved Products: Two commercial BCMA CAR-T therapies (Equecabtagene Autoleucel and Zevorcabtagene Autoleucel) are fully approved in China for adult relapsed/refractory multiple myeloma.
• International Medical Centers (IMCs): Recognized hematology centers in Beijing, Shanghai, Guangzhou, and Tianjin admit overseas patients through their International Healthcare Departments as self-pay medical travelers.
• Formal Hospital Billing: All payments for commercial cell products and hospital stays are wired directly to the hospital's official institutional account, backed by formal government-regulated medical invoices.

For comprehensive details on commercial pricing, hospital pathways, and visa guidance, please refer to our dedicated independent guide: CAR-T Therapy in China for International Patients.

This document is published by China Myeloma Digital Network (CMDN) as an independent public interest resource. We do not accept commissions, broker fees, or commercial referrals.